Polyclonal antibodies and mAbs specifically recognize VAMP-7. (A) 20 μg of PNS from rat kidney was probed for VAMP-7 with an affinity-purified polyclonal and five different mAbs. A 25-kD band is recognized by all antibodies. (B) The domain of VAMP-7 recognized by the mAbs was mapped. The transmembrane (TM) region corresponds to the predicted membrane anchor. The coil domain is recognized by three antibodies and a more NH₂-terminal domain by two antibodies.

VAMP-7 partially colocalizes with an LE and lysosomal marker in NIH-3T3 cells. VAMP-7 immunoreactivity (Texas red; A, D, and G) is compared with immunofluorescence (FITC) of LAMP-1 (B), p115 (E), or TfR (H). C, F, and I are the merged images. Arrowheads in A–C point to puncta that are immunoreactive for both VAMP-7 and LAMP-1. Bar, 10 μm.

VAMP-7 is broadly expressed and associates with membranes. (A) Seven tissues and PC12 cells were probed with the polyclonal antibody for VAMP-7 expression as described in the text and Materials and Methods. 20 μg of PNS was used for each tissue. (B) PNS was fractionated into cytosolic and membrane fractions. The membrane pellet was extracted with 1.5 M NaCl, pH 11.0, or 2% Triton X-100 and centrifuged into supernatant (S) or pellet (P) fractions.

VAMP-7 colocalizes with lgp120 in LEs and is present on MPR-negative transport vesicles. PC12 cells double-immunogold–labeled for (A) the CD-MPR (MPR, 10 nm gold) and VAMP-7 (15 nm gold), and (B) VAMP-7 (10 nm gold) and lgp120 (15 nm gold). (A) The small arrowheads point to small-sized, electron-dense transport vesicles that contain the MPR but not VAMP-7. VAMP-7 is found on larger vesicles (large arrowheads) with a less electron-dense content (see also Fig. 5 C). (B) VAMP-7 colocalizes with lgp120 to the limiting membrane of an LE. The arrow points to a connection between a VAMP-7–positive vesicle that is in continuity with the vacuolar region of the LE. G, Golgi complex; L, lysosome; M, mitochondrion. Bars, 200 nm.

Distribution of VAMP-7 immunoreactivity in nocodozole- and BFA-treated NIH-3T3 cells. (A–F) Nocodozole-treated cells stained for VAMP-7 (A and D), LAMP-1 (B), or TfR (E). (G–L) BFA-treated cells stained for VAMP-7 (G and J), LAMP-1 (H), or TfR (K). Bar, 10 μm.

VAMP-7 is localized to the TGN, LEs, and transport vesicles. Ultrathin cryosections of PC12 cells immunogold-labeled (10 nm gold) for VAMP-7. In A and B, the signal for VAMP-7 was enhanced by using an intermediate swine anti–rabbit IgG antibody. (A) Overview of the perinuclear area. VAMP-7 is present in the Golgi complex (indicated by G) and many of the tubulovesicular membranes of the TGN. The open star indicates an immature secretory granule, as judged by the electron-dense cytosolic clathrin coat. The filled stars indicate mature secretory granules. No significant label is found over these secretory compartments. (B) VAMP-7 is present on the limiting membrane of an LE. (C) LE-associated vesicles. L, lysosome; M, mitochondrion. Bars, 200 nm.

HeLa cells recycle Tf and break down EGF. (A) ¹²⁵I-EGF or -Tf was loaded into cells and then chased into the supernatant. Tf was recovered in a TCA-precipitable form with a half-life of ∼20 min (open circles). EGF is recovered in two forms, TCA precipitated or intact (open triangles) and non-TCA precipitated or degraded (filled circles). The intact form of EGF rapidly appears in the cell media while the degraded form begins to appear after ∼40 min and continues to increase throughout the 120-min period. (B) Cells loaded with ¹²⁵I-EGF were permeabilized with SLO. ¹²⁵I-EGF degradation was measured in the presence (open circles) and absence (filled circles) of cytosol. EGF degradation proceeds with similar kinetics in permeabilized and intact cells.

VAMP-7 antibodies block EGF breakdown. (A) NEM treatment blocks the degradation of EGF, but addition of IgG or anti–syntaxin 6 antibodies has no effect on the process. Addition of anti–VAMP-7 antibodies partially blocks degradation of EGF. Measurements were made three times and the standard deviation is indicated. An F-test indicated that the effect observed with anti–VAMP-7 antibodies was statistically significant compared with control antibodies (P < 0.01). (B) Anti–VAMP-7 affinity-purified polyclonal antibody also inhibits EGF breakdown. Including VAMP-7 protein but not GST reverses the inhibition of EGF degradation produced by the anti–VAMP-7 polyclonal antibody. VAMP-7 protein and GST alone have no effect in the assay. Measurements were made two times and the average is plotted. (C) Increasing amounts of VAMP-7 polyclonal or monoclonal antibodies result in an increased inhibition of EGF breakdown. Maximum inhibition is achieved at a concentration of 100 μg/ml VAMP-7 antibodies. Filled circles indicate polyclonal antibodies; open circles indicate mAbs. (D) EGF-loaded cells were chased for varying amounts of time at 37°C followed by SLO-permeabilization. Cells were then incubated with antibody and EGF degradation measured as described above. (E) Tf recycling is also reconstituted by addition of cytoplasm to SLO-permeabilized cells. Whereas NEM inhibits the recycling, neither IgG nor anti–VAMP-7 antibodies affect the process.